HRA Pharma Launches ellaOne(R) in Europe
a privately-held, European pharmaceutical company that designs products,
devices and supporting services in reproductive health and endocrinology,
announced today that ellaOne(R) (ulipristal acetate, 30mg), its new
generation emergency contraceptive, has been launched in
the
ellaOne in all European countries over the coming months.
ellaOne(R) is the first representative of a new therapeutic class,
selective progesterone receptor modulators, and is the first molecule to have
been specifically designed and developed for use as an oral emergency
contraceptive. Clinical trials performed on more than 4000 women have shown
that a single dose of ellaOne significantly reduces the number of pregnancies
versus the number of expected pregnancies in absence of emergency
contraception. ellaOne is different from currently used levonorgestrel-based
emergency contraceptives, in that it maintains efficacy for 5 days after
unprotected intercourse while its safety and tolerability profile has been
demonstrated to be comparable to that of levonorgestrel.
“Our company is committed to advancing the discovery and development of
new medicines tackling unmet needs in the field of reproductive health,” said
of more than 10 years of research and development and represents an important
milestone, as it is the first licensed product to have been specifically
designed and developed for use as an oral emergency contraceptive.”
Since pioneering the launch of levonorgestrel for emergency contraception
in 1999, HRA Pharma has been a leader in emergency contraception, providing
solutions to unmet needs for millions of women in over 50 countries. The
European launch of ellaOne is the first step in the international
commercialisation of this product. The company plans to file for marketing
approvals in countries worldwide under the trademarks ellaOne and ella, and
continues to develop innovative projects in the field of reproductive health.
About HRA Pharma
HRA Pharma is an emerging, privately-held European pharmaceutical company
that designs products, devices and supporting services in niche areas of
health and makes them available to doctors and patients worldwide. The
company targets therapeutic gaps in the areas of reproductive health and
endocrinology, and uses innovative marketing solutions and socially-conscious
programs, such as contraception education in developing countries, to promote
healthy management of drugs and diseases. A pioneer in emergency
contraception, its product NorLevo was the first emergency contraceptive
based on one type of progesterone to be approved for sale by health
authorities. Headquartered in
manufacturing, distribution and NGO partners which enables it to satisfy
critical patient needs and improve patient health in over 50 countries across
the globe. Visit http://www.hrapharma.com for more information.
SOURCE HRA Pharma